Levodopa/carbidopa/entacapone intestinal gel (Lecigon®). HTA ID: 21068

Assessment Status Rapid Review Complete
HTA ID 21068
Drug Levodopa/carbidopa/entacapone intestinal gel
Brand Lecigon®
Indication For the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson’s medicinal products have not given satisfactory results.
Assessment Process
Rapid review commissioned 20/12/2021
Rapid review completed 17/02/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that levodopa/carbidopa/entacapone intestinal gel not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations-November 2022.